Atea Pharmaceuticals (AVIR) Operating Expenses (2020 - 2022)
Historic Operating Expenses for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to $39.9 million.
- Atea Pharmaceuticals' Operating Expenses fell 4380.34% to $39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $130.6 million, marking a year-over-year decrease of 3865.94%. This contributed to the annual value of $193.0 million for FY2024, which is 1753.63% up from last year.
- According to the latest figures from Q4 2022, Atea Pharmaceuticals' Operating Expenses is $39.9 million, which was down 4380.34% from $16.3 million recorded in Q3 2022.
- Atea Pharmaceuticals' Operating Expenses' 5-year high stood at $71.0 million during Q4 2021, with a 5-year trough of $10.0 million in Q2 2020.
- Over the past 3 years, Atea Pharmaceuticals' median Operating Expenses value was $35.3 million (recorded in 2021), while the average stood at $36.3 million.
- Per our database at Business Quant, Atea Pharmaceuticals' Operating Expenses skyrocketed by 41688.49% in 2021 and then crashed by 7037.56% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' Operating Expenses (Quarter) stood at $28.0 million in 2020, then soared by 153.69% to $71.0 million in 2021, then crashed by 43.8% to $39.9 million in 2022.
- Its Operating Expenses was $39.9 million in Q4 2022, compared to $16.3 million in Q3 2022 and $32.3 million in Q2 2022.